- Home
- EXEL vs SSNC Comparison
EXEL vs SSNC Comparison
Compare EXEL & SSNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | SSNC |
|---|---|---|
| Founded | 1994 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 15.9B |
| IPO Year | 2000 | 2007 |
Fundamental Metrics
Financial Performance| Metric | EXEL | SSNC |
|---|---|---|
| Price | $56.10 | $67.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 8 |
| Target Price | $46.50 | ★ $96.13 |
| AVG Volume (30 Days) | ★ 2.5M | 1.7M |
| Earning Date | 05-05-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 1.55% |
| EPS Growth | ★ 57.95 | 5.00 |
| EPS | 0.79 | ★ 0.91 |
| Revenue | $452,477,000.00 | ★ $1,675,295,000.00 |
| Revenue This Year | $13.61 | $9.20 |
| Revenue Next Year | $13.13 | $4.69 |
| P/E Ratio | ★ $70.29 | $76.31 |
| Revenue Growth | N/A | ★ 13.09 |
| 52 Week Low | $33.76 | $61.40 |
| 52 Week High | $57.57 | $91.07 |
Technical Indicators
Market Signals| Indicator | EXEL | SSNC |
|---|---|---|
| Relative Strength Index (RSI) | 60.64 | 53.04 |
| Support Level | $40.77 | $65.15 |
| Resistance Level | $57.57 | $70.24 |
| Average True Range (ATR) | 1.41 | 1.64 |
| MACD | -0.17 | 0.46 |
| Stochastic Oscillator | 69.69 | 63.93 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About SSNC SS&C Technologies Holdings Inc.
SS&C Technologies provides software products and software-enabled services to a variety of customers primarily in financial services. Acquisitions are a large part of SS&C's history. SS&C GlobeOp provides fund administration services to alternative and traditional asset managers. In addition, SS&C provides portfolio accounting, portfolio management, trading, banking/lending, and other software to asset managers, banks, and financial advisors. SS&C's purchase of Intralinks makes it a leading player in virtual deal room solutions. With its 2018 purchase of DST Systems, SS&C gained a foothold in the healthcare industry with pharmacy health management solutions and medical claim administration services. In 2022, SS&C acquired robotic process automation software firm Blue Prism.